CG-0255 is a revolutionary new generation antiplatelet drug targeting P2Y12 receptor.  It is world’s first non-disulfide thiol based prodrug that replies only on esterases for one-step, fast and uniform hydrolytic activation.  It is also world’s first irreversible P2Y12 antagonist for IV injection.  CG-0255 is expected to be approved for percutaneous coronary intervention (PCI), perioperative antiplatelet therapy, perioperative antiplatelet therapy for mechanical thrombectomy in stroke.  CG-0255 fulfils unmet medical needs and can be applied broadly to address various clinical shortcomings.

CG-0255 is a revolutionary new generation antiplatelet drug targeting P2Y12 receptor.  It is world’s first non-disulfide thiol based prodrug that replies only on esterases for one-step, fast and uniform hydrolytic activation.  CG-0255 has been shown to have good dose linearity, minimal individual PK/PD variation in human, and excellent balance between antiplatelet effect and bleeding risk.  CG-0255 is expected to be approved through a special and expedited regulatory process for long term treatment of acute coronary syndrome (ACS), myocardial infarction (MI), stroke, and peripheral arterial disease (PAD).

According to the recent expert consensus in area of hepatitis B treatment, neither the nucleoside (tide) analog antiviral drugs widely used at present nor interferon drugs are sufficient to universally improve the clinical cure outcomes of hepatitis B. To achieve the clinical goal of functional cure for hepatitis B, it is necessary to integrate various methods such as direct antiviral treatment, suppression of HBV gene expression and immunoregulation. To achieve the ideal clinical endpoint, the above methods should be used in combination or sequentially according to the diversity of the patient's baseline conditions. The CG2021S project is part of the comprehensive strategy for the functional cure of chronic hepatitis B by Curegene Pharmaceutical, using innovative technology to effectively reduce the biomarkers such as HBV DNA and HBsAg in patients with chronic hepatitis B, thereby alleviating the suppression of the immune response of the body.

According to the recent expert consensus on hepatitis B treatment, neither the currently widely used nucleoside/nucleotide antiviral drugs nor interferons are sufficient to broadly improve the functional cure of hepatitis B. To truly achieve HBV functional cure, it is necessary to combine approaches of direct antiviral, HBV gene expression suppression, and immune reactivation.  These treatment options may be used jointly or sequentially according to conditions of each individual patient in order to achieve the ideal clinical endpoint.  The CG-2021V project is part of a comprehensive strategy for the functional cure of chronic hepatitis B, based on CureGene core platform. It uses innovative mRNA technology to effectively stimulate the body's immune system for immune reactivation, and therefore eliminate hepatitis B virus. This product will be combined with CureGene's siRNA product to form our combination solution for functional cure of chronic hepatitis B.